Gavreto prescribing information 2024 manufacturer?

Who makes Gavreto and when was it approved?
Gavreto is a tyrosine kinase inhibitor indicated for the treatment of people with non-small cell lung cancer (NSCLC) whose tumors have a specific genetic mutation. It is made by Ipsen.

Gavreto prescribing information and manufacturer for 2024:

Gavreto received FDA approval in March 2022 for the treatment of metastatic non-small cell lung cancer (NSCLC) with RET mutations. According to Ipsen's official website, as of 2024, Gavreto is still available on the market and is manufactured by Ipsen [1].

Clinical trials and regulatory approvals:

Gavreto has been the subject of various clinical trials to evaluate its efficacy and safety in various genetic subtypes of NSCLC.

References:
[1] https://www.ipsen.com/en/products/gavreto#:~:text=Gavreto%20%2D%20Tyrosine%20Kinase%20Inhibitor%2C%20For%20Metastatic%20Non-,Ipsen%20Pharmaceuticals%20Inc.-,Gavreto%20%7C%20Tyrosine%20Kinase%20Inhibitor%20(PD-2021%2C%202021)-